POLARx Cardiac Cryoablation System Study

Inclusion Criteria: 1. Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use; 2. Subjects who are willing and capable of providing informed consent; 3. Subjects who are willing and capable of participating in all testing associated with this clinical study at an approved clinical investigational center; 4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law. Exclusion Criteria: 1. Any known contraindication to an AF ablation or anticoagulation, including those listed in the instructions for use; 2. Subjects with indication for treatment of AF that is not according to current and future Guidelines and system indications for use; 3. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause; 4. Known or pre-existing severe Pulmonary Vein Stenosis; 5. Evidence of myxoma, LA thrombus or intracardiac mural thrombus; 6. Previous cardiac surgery (e.g. ventriculotomy or atriotomy, CABG, PTCA, stent procedure) within 90 days prior to enrollment; 7. Implantable cardiac device procedures (e.g. PM, ICD, CRT) within 30 days prior to enrollment; 8. Implanted Left Atrial Appendage Closure device prior to the index procedure; 9. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder; 10. Subjects with severe valvular disease OR with a prosthetic - mechanical or biological - heart valve (not including valve repair and annular rings); 11. Presence of any pulmonary vein stents; 12. Active systemic infection; 13. Vena cava embolic protection filter devices and/ or known femoral thrombus; 14. Any previous history of cryoglobulinemia; 15. History of blood clotting or bleeding disease; 16. Any prior history of documented cerebral infarct, TIA or systemic embolism (excluding a post-operative deep vein thrombosis (DVT)) ≤ 180 days prior to enrollment; 17. Subjects who are hemodynamically unstable; 18. The subject is unable or not willing to complete follow-up visits and examination for the duration of the study; 19. Life expectancy ≤ 1 year per investigator's opinion; 20. Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon investigator's discretion); 21. Unrecovered/unresolved Adverse Events from any previous invasive Procedure; 22. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility.